Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.

P2Y₁₂ Inhibitor versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Trials – European Heart Journal Open

Commentary: Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention – TCTMD

Commentary on Twitter

Happy to share our paper in @ESC_Journals. In this meta-analysis of randomized trials, we found that as compared with aspirin, P2Y12i was associated with 11% and 19% reduction in MACE and MI respectively. https://t.co/Y3Gstzgfu6

— Devika Aggarwal (@devikagg) March 30, 2022